Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Trial Profile

Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs LY 3303560 (Primary) ; LY 3303560 (Primary) ; Florbetapir F 18; Flortaucipir F 18
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 May 2020 to 1 Feb 2020.
    • 31 Aug 2017 Planned primary completion date changed from 1 May 2020 to 1 Feb 2020.
    • 03 May 2017 Planned End Date changed from 17 Apr 2020 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top